SCM
LBRX

Sterling Capital Management’s LB Pharmaceuticals LBRX Stock Holding History

Sterling Capital Management’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.89K Sell
274
-94
-26% -$2.76K ﹤0.01% 2287
2026
Q1 		$9.07K Sell
368
-224
-38% -$5.17K ﹤0.01% 2422
2025
Q4 		$13.2K Buy
+592
New +$10.3K ﹤0.01% 2469

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Sterling Capital Management's LBRX Position: Q2 2026 in Review

Sterling Capital Management reduced its LB Pharmaceuticals (LBRX) stake by 26% in Q2 2026, selling an estimated $2.76K and leaving 274 shares worth $8.89K. The position accounts for ﹤0.01% of the portfolio, ranked #2287.

Sterling Capital Management first reported a position in LBRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $13.2K in Q4 2025. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Sterling Capital Management held 274 shares of LB Pharmaceuticals worth $8.89K as of Q2 2026.
  • Sterling Capital Management sold 94 LB Pharmaceuticals shares in Q2 2026, an estimated $2.76K.
  • LB Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2287 holding.
  • Sterling Capital Management first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Sterling Capital Management's LB Pharmaceuticals position peaked at $13.2K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.